JMKX003142 from Jemincare is an oral small molecule in Phase 2 for ADPKD in China. Its mechanism has not been publicly disclosed.
Background
Jemincare is a Chinese pharmaceutical company that has moved JMKX003142 into Phase 2 for rapidly progressive ADPKD. Like ABBV-CLS-628, the mechanism of action has not been publicly disclosed. Multiple Phase 1 pharmacokinetic and drug-drug interaction studies are also ongoing, suggesting an active development program.
How It Works
The mechanism of action is not publicly disclosed. Based on the oral route, small molecule nature, and target population (rapidly progressive ADPKD with TKV endpoint), it may target cAMP signaling, mTOR, or cell proliferation pathways — but this is speculation. The company has not published preclinical data in English-language journals.
Clinical Trial Details
The Phase 2 trial (NCT06800651) is recruiting 135 patients with rapidly progressive ADPKD in China. The primary endpoint is TKV reduction. Started March 2025 with estimated completion in 2027. Multiple Phase 1 PK/DDI studies are also running in parallel.
Why It's Promising
If successful, JMKX003142 could provide an oral treatment option. The rapid progression from Phase 1 to Phase 2 (with 135 patients) suggests confidence in the data. However, results and regulatory approval in China may not immediately translate to Western markets.
Limitations & Concerns
No published preclinical or Phase 1 data. Undisclosed mechanism makes scientific evaluation impossible. Chinese regulatory pathway may not align with FDA/EMA requirements for global approval. Limited English-language information available.